Iqymune (Human Normal Immunoglobulin)

Iqymune is an immunoglobulin replacement product used to restore humoral immunity in various immunodeficiency conditions.

• Primary immunodeficiency diseases: supplies pooled IgG antibodies to reduce infection frequency and severity.
• Secondary immunodeficiency: provides antibody support for patients with acquired immune deficits, such as after chemotherapy or HIV infection.
• Bone marrow or stem‑cell transplant recipients: helps reconstitute antibody production during the post‑transplant period.

• Human normal immunoglobulin in Iqymune consists of pooled IgG antibodies derived from healthy donors. After intravenous infusion, the antibodies circulate in the plasma, binding to pathogens and toxins, neutralizing them, and facilitating opsonization. The product also modulates immune cell activity, helping to restore deficient humoral immunity and reduce inflammatory responses in immunodeficient patients.

Common Side Effects

• Headache: mild to moderate pain often occurring during or shortly after infusion.
• Fever or chills: transient temperature elevation related to immune activation.
• Nausea or vomiting: gastrointestinal discomfort during infusion.
• Fatigue: temporary tiredness following administration.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Thromboembolic events: clot formation that may lead to vascular occlusion.
• Renal dysfunction: impaired kidney function, especially with high‑dose or rapid infusions.
• Aseptic meningitis: inflammation of the meninges without infection.
• Hemolysis: destruction of red blood cells leading to anemia.
• Severe thrombocytopenia: markedly low platelet counts increasing bleeding risk.

Before initiating therapy, clinicians should evaluate patient history and baseline immunoglobulin levels.

• Assess IgG levels: determine need for replacement and appropriate dosing.
• Monitor infusion reactions: observe vital signs and symptoms during and after administration.
• Adjust infusion rate: slower rates for patients with cardiovascular disease or prior reactions.
• Avoid in patients with known anti‑IgA antibodies and IgA deficiency: risk of severe anaphylaxis.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human normal immunoglobulin may interact with other agents that affect immune function or coagulation.

Major Interactions (Avoid)

• Live vaccines: immunoglobulin can neutralize vaccine efficacy, rendering immunization ineffective.
• High‑dose corticosteroids: may increase risk of infection despite immunoglobulin therapy.

Moderate Interactions (Monitor Closely)

• Immunosuppressive drugs (e.g., azathioprine, mycophenolate): monitor for additive infection risk.
• Anticoagulants (e.g., warfarin): watch for altered bleeding parameters.
• Cytotoxic chemotherapy: coordinate timing to avoid overlapping immunosuppression.